Clinical Trials Logo

Clinical Trial Summary

This study is being conducted to better understand the natural course of GM1 gangliosidosis, GM2 gangliosidoses and Gaucher disease Type 2 (GD2). Information is planned to be gathered on at least 180 patients with GM1 gangliosidosis, GM2 gangliosidoses, and Gaucher Disease type 2. Retrospective data collection is planned for at least 150 deceased patients (Group A). Group B is for patients alive at the time of enrollment. In Group B it is planned to prospectively collect more comprehensive data from at least 30 patients. The purpose of this study is to collect relevant information for a adequate design of a potential subsequent research program in these diseases. In this study no therapy is being offered.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04470713
Study type Observational
Source Idorsia Pharmaceuticals Ltd.
Contact
Status Completed
Phase
Start date July 31, 2019
Completion date October 30, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT02254863 - UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells Phase 1
Recruiting NCT04624789 - Registry Gangliosidoses
Completed NCT03759665 - N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease) Phase 2
Active, not recruiting NCT04221451 - A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2 Phase 3
Completed NCT00672022 - Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses Phase 3
Completed NCT00176904 - Stem Cell Transplant for Inborn Errors of Metabolism Phase 2/Phase 3
Active, not recruiting NCT04669535 - A Dose-escalation and Safety & Efficacy Study of AXO-AAV-GM2 in Tay-Sachs or Sandhoff Disease Phase 1
Recruiting NCT03333200 - Longitudinal Study of Neurodegenerative Disorders
Active, not recruiting NCT05109793 - GM1 and GM2 Gangliosidosis PROspective Neurological Disease TrajectOry Study (PRONTO)
Terminated NCT02030015 - Synergistic Enteral Regimen for Treatment of the Gangliosidoses Phase 4
Recruiting NCT00668187 - A Natural History Study of the Gangliosidoses
Completed NCT01869270 - Gene Therapy for Tay-Sachs Disease N/A
Completed NCT01102686 - Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease) Phase 1/Phase 2
Terminated NCT01372228 - Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders Phase 1/Phase 2